Metformin Suppresses Glioblastoma Tumor Growth and Progression Through the AMPK/FoxO3a/Survivin Axis - PubMed
8 days ago
- #metformin
- #glioblastoma
- #AMPK/FoxO3a/survivin
- Metformin (MET) shows potential anticancer effects in glioblastoma (GB) by inhibiting tumor growth and progression.
- The study focuses on survivin, a key protein in GB cell survival, resistance to therapy, and tumor recurrence.
- MET inhibits GB cell viability, migration, and invasion via the AMPK/FoxO3a/survivin pathway.
- In vivo studies confirm increased FoxO3a and decreased survivin in metformin-treated mice.
- Findings suggest repurposing MET as an adjuvant treatment for GB.